WO2000009525A3 - Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments - Google Patents

Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments Download PDF

Info

Publication number
WO2000009525A3
WO2000009525A3 PCT/US1999/017712 US9917712W WO0009525A3 WO 2000009525 A3 WO2000009525 A3 WO 2000009525A3 US 9917712 W US9917712 W US 9917712W WO 0009525 A3 WO0009525 A3 WO 0009525A3
Authority
WO
WIPO (PCT)
Prior art keywords
agent
cancer
lung
mrna
treatments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/017712
Other languages
French (fr)
Other versions
WO2000009525A2 (en
Inventor
Jonathan W Nyce
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
East Carolina University
Original Assignee
East Carolina University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by East Carolina University filed Critical East Carolina University
Priority to CA002333901A priority Critical patent/CA2333901A1/en
Priority to HK02102614.0A priority patent/HK1042706A1/en
Priority to AU53374/99A priority patent/AU5337499A/en
Priority to EP99939006A priority patent/EP1102786A4/en
Publication of WO2000009525A2 publication Critical patent/WO2000009525A2/en
Publication of WO2000009525A3 publication Critical patent/WO2000009525A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

A composition comprises a nucleic acid comprising an oligo anti-sense to a target such as polypeptide(s) associated with an ailment afflicting lung airways, genes and mRNAs encoding them, genomic and mRNA flanking regions, intron and exon borders and all regulatory and functionally related segments of the genes and mRNAs encoding the polypeptides, their salts and mixtures. Various formulations contain a requisite carrier, and optionally other additives and biologically active agents. The agent of the invention may be prepared by selecting a target gene(s), genomic flanking region(s), RNA(s) and/or polypeptide(s) associated with a disease(s) or condition(s) afflicting lung airways, obtaining the sequence of the mRNA(s) corresponding to the target gene(s) and/or genomic flanking region(s), and/or RNAs encoding the target polypeptide(s), selecting at least one segment of the mRNA which may be up to 60 % free of thymidine (T) and synthesizing one or more anti-sense oligonucleotide(s) to the mRNA segments which are free of adenosine (A) by substituting a universal base for A when present in the oligonucleotide. The agent may be prepared by selection of target nucleic acid sequences with GC running stretches, which have low T content, and by optionally replacing A in the anti-sense oligonucleotides with a AUniversal base@. The agent, composition and formulations are used for prophylactic, preventive and therapeutic treatment of ailments associated with impaired respiration, allergy(ies) and/or inflammation, such as pulmonary vasoconstriction, inflammation, allergies, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, pulmonary hypertension and bronchoconstriction, chronic bronchitis, emphysema, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), ischemic conditions including ischemia itself, and cancers such as leukemias, lymphomas, carcinomas, and the like, e.g. colon cancer, breast cancer, pancreatic cancer, lung cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastasis, etc., as well as all types of cancers with may metastasize or have metastasized to the lung(s), including breast and prostate cancer. The present treatment is suitable for administration in combination with other treatments, e.g. before, during and after other treatments, including radiation, chemotherapy, antibody therapy and surgery, among others. The present agent is effectively administered preventatively, prophylactically or therapeutically by itself for conditions without known therapies, or as a substitute for, or in conjunction with, other therapies exhibiting undesirable side effects. The treatment of this invention may be administered directly into the respiratory system of a subject, so that the agent has direct access to the airways and the lungs.
PCT/US1999/017712 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments Ceased WO2000009525A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002333901A CA2333901A1 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
HK02102614.0A HK1042706A1 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
AU53374/99A AU5337499A (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
EP99939006A EP1102786A4 (en) 1998-08-03 1999-08-03 ANTISENSE OLIGONUCLEOTIDS WITH LOW ADENOSINE CONTENT, PREPARATION, KIT AND TREATMENT METHODS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9521298P 1998-08-03 1998-08-03
US60/095,212 1998-08-03

Publications (2)

Publication Number Publication Date
WO2000009525A2 WO2000009525A2 (en) 2000-02-24
WO2000009525A3 true WO2000009525A3 (en) 2000-05-18

Family

ID=22250687

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/017712 Ceased WO2000009525A2 (en) 1998-08-03 1999-08-03 Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments

Country Status (6)

Country Link
EP (1) EP1102786A4 (en)
CN (1) CN1317009A (en)
AU (1) AU5337499A (en)
CA (1) CA2333901A1 (en)
HK (1) HK1042706A1 (en)
WO (1) WO2000009525A2 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160546B2 (en) 1995-06-06 2007-01-09 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7501123B2 (en) 2004-03-12 2009-03-10 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825174B2 (en) 1995-06-07 2004-11-30 East Carolina University Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
US7034007B1 (en) 1995-06-07 2006-04-25 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
EP1165123A4 (en) * 1999-03-26 2002-09-11 Human Genome Sciences Inc 48 HUMAN SECRETED PROTEINS
EP1165783A4 (en) * 1999-03-26 2002-09-11 Human Genome Sciences Inc 47 HUMAN SECRETED PROTEINS
WO2000062736A2 (en) * 1999-04-06 2000-10-26 East Carolina University Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
US6489151B1 (en) * 2000-03-27 2002-12-03 The Research Foundation Of State University Of New York Biologically active alternative form of the IKKα IκB kinase
DE10019252A1 (en) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydeoxyribonucleotides to inhibit ICAM-1 gene expression
DE10049549A1 (en) * 2000-10-06 2002-05-02 Markus Hecker Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40
US7745420B2 (en) * 2001-07-06 2010-06-29 Topigen Pharmaceutique, Inc. Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
US20060088835A1 (en) * 2002-04-05 2006-04-27 Pickard Benjamin S Schizophrenia associated genes
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
CN1322899C (en) * 2004-02-11 2007-06-27 中国科学院上海生命科学研究院 Anti-liver cancer gene drug composition, small molecule interfering RNA and screening method thereof
NZ554723A (en) 2004-10-29 2009-12-24 Topigen Pharmaceuticals Inc Antisense oligonucleotides against CCR3 chemokine receptor
MX2008002101A (en) 2005-08-12 2008-04-19 Schering Corp Mcp1 fusions.
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US10017762B2 (en) * 2010-11-24 2018-07-10 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for treating or preventing lupus
BR112013032223A2 (en) * 2011-06-15 2016-12-20 Grifols Therapeutics Inc isolated nucleic acid molecule and composition
CN102866153B (en) * 2012-09-29 2014-08-13 郑州安图生物工程股份有限公司 Prostatitis joint-detection kit
WO2014164805A1 (en) * 2013-03-11 2014-10-09 University Of North Carolina At Chapel Hill Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing
JP2023548597A (en) * 2020-10-29 2023-11-17 エー． ガルシア－ブランコ，マリアーノ Soluble interleukin-7 receptor (sIL7R) modulation therapy to treat cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3222793A (en) * 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6498147B2 (en) * 1992-05-22 2002-12-24 The Scripps Research Institute Suppression of nuclear factor-κb dependent processes using oligonucleotides
US5994315A (en) * 1995-06-07 1999-11-30 East Carolina University Low adenosine agent, composition, kit and method for treatment of airway disease
US5856462A (en) * 1996-09-10 1999-01-05 Hybridon Incorporated Oligonucleotides having modified CpG dinucleosides
JP2002515513A (en) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for pulmonary delivery of nucleic acids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932557A (en) * 1997-08-12 1999-08-03 Mustafa; S. Jamal Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NYCE ET AL.: "DNA antisense therapy for asthma in an animal model", NATURE,, vol. 385, 20 February 1997 (1997-02-20), pages 721 - 725, XP002923989 *
See also references of EP1102786A4 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160546B2 (en) 1995-06-06 2007-01-09 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7501123B2 (en) 2004-03-12 2009-03-10 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10

Also Published As

Publication number Publication date
AU5337499A (en) 2000-03-06
WO2000009525A2 (en) 2000-02-24
CN1317009A (en) 2001-10-10
EP1102786A4 (en) 2002-03-06
CA2333901A1 (en) 2000-02-24
EP1102786A2 (en) 2001-05-30
HK1042706A1 (en) 2002-08-23

Similar Documents

Publication Publication Date Title
WO2000009525A3 (en) Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
US10369232B2 (en) Allele selective gene editing and uses thereof
EP1465995B1 (en) Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
ATE279525T1 (en) GENE THERAPY FOR SOLID TUMORS, PAPILLOMAS AND WARTS
TW202529777A (en) Combination therapy
Gopalan et al. Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response
EP2386312A3 (en) Intrathecal and intratumoral superantigens to treat malignant disease
BR0006019A (en) Low adenosine antisense oligonucleotide, compositions, kit & method for treating airway disorders associated with bronchoconstriction, lung inflammation, allergy (s) & surfactant depletion
JP2021505200A5 (en)
TW202408541A (en) Formulations for modulating myc expression
Koutsilieris et al. Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone‐refractory prostate cancer: Case report
JP5406024B2 (en) Cancer therapy using Bcl-XL specific siNA
MXPA01008870A (en) Method for validating/invalidating target(s) and pathways.
ES2201611T3 (en) USE OF MAGNESIUM (MG2 +) TO INCREASE THE INTRODUCTION OF GENES IN GENE THERAPY.
US20240067684A1 (en) Constitutively active payloads
JP2024530169A (en) method
Lokich Metastatic adamantinoma of bone to lung: a case report of the natural history and the use of chemotherapy and radiation therapy
Baba et al. Ha‐ras mutations in N‐nitrosomorpholine‐induced lesions and inhibition of hepatocarcinogenesis by antisense sequences in rat liver
Nyce Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
WO2001057069A3 (en) Targeting peptides
Wasko et al. Survivin expression in pituitary adenomas
Costa-Pereira et al. Molecular and cellular biology of prostate cancer—the role of apoptosis as a target for therapy
JP2003503052A (en) Antisense oligonucleotides that regulate cyclin E gene expression and their use in therapy
US20230151363A1 (en) Modified short-interfering rna compositions and their use in the treatment of cancer
Loriguet et al. 243 Sarcomatoid carcinoma in Head and Neck cancers: Clinical features and prognosis

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99809303.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA CN MX RU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA CN MX RU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 53374/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2333901

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000971

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1999939006

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999939006

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999939006

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)